Trends in breast cancer incidence associated with reductions in the use of hormone replacement therapy

Cancer Epidemiology

Volumn 35, Issue 1, 2011, Pages 11-16

  Silverman, Barbara G ^a   Siegelmann Danieli, Nava ^a   Braunstein, Rony ^b   Kokia, Ehud S ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Independent Statistical Consultant for Bio Medical Research   (Israel)

Author keywords

Breast cancer; Epidemiology; Hormone replacement therapy

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CHI SQUARE TEST; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; ISRAEL; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MODEL; PHARMACY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK REDUCTION; STATISTICAL ANALYSIS;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MIDDLE AGED; PROGNOSIS;

EID: 79951553715     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.11.006     Document Type: Article

References (32)

1. Hersh A.L., Stefanick M.L., Stafford R.S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004, 291:47-53.
2. Wysowski D.K., Governale L.A. Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf 2005, 14:171-176.
3. Hartsfield C.L., Connelly M.T., Newton K.M., Andrade S.E., Wei F., Buist D.S. Health system responses to the Women's Health Initiative findings on estrogen and progestin: organizational response. J Natl Cancer Inst Monogr 2005, 35:113-115.
4. Hing E., Brett K.M. Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003. Obstet Gynecol 2006, 108:33-40.
5. Buist D.S., Newton K.M., Miglioretti D.L., Beverly K., Connelly M.T., Andrade S., et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004, 104:1042-1050.
6. Menon U., Burnell M., Sharma A., Gentry-Maharaj A., Fraser L., Ryan A., et al. Decline in use of hormone therapy among postmenopausal women in the United Kingdom. Menopause 2007, 14:462-467. UKCTOCS Group.
7. Parazzini F. Trends of determinants of hormone therapy use in Italian women attending menopause clinics, 1997-2003. Menopause 2008, 15:164-170. Progetto Menopausa Italia Study Group.
8. Faber A., Bouvy M.L., Loskamp L., van de Berg P.B., Egberts T.C.G., de Jong-van den Berg L.T.W. Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study. Br J Clin Pharmacol 2005, 60:641-647.
9. Wegienka G., Havstad S., Kelsey J.L. Menopausal hormone therapy in a health maintenance organization before and after Women's Health Initiative hormone trials termination. J Womens Health 2006, 15:369-378.
10. Haas J.S., Kaplan C.P., Gerstenberger E.P., Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004, 140:184-188.
11. Majumdar S.R., Almasi E.A., Stafford R.S. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 2004, 292:1983-1988.
12. Silverman B.G., Kokia E.S. Use of hormone replacement therapy, 1998-2007: sustained impact of the Women's Health Initiative findings. Ann Pharmacother 2009, 43(2):251-258.
13. Ravdin P.M., Cronin K.A., Howlader N., Berg C.D., Chlebowski R.T., Feuer E.J., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007, 356:1670-1674.
14. Glass A.G., Lacy J.V., Carreon J.D., Hoover R.N. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007, 99:1152-1161.
15. Canfell K., Banks E., Moa A.M., Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008, 188:641-644.
16. Jemal A., Ward E., Thun M. Research trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007, 9:R28.
17. Clarke C.A., Glaser S.L., Uratsu C.S., Selby J.V., Kushi L.H., Herrinton L.J. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006, 24:e49-50.
18. Kerlikowske K., Miglioretti D.L., Buist D.S.M., Walker R., Carney P.A. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007, 99:1335-1339.
19. Kliewer E.V., Demers A.A., Nugent Z.J. A decline in breast cancer incidence. NEJM 2007, 357:509-510. [Letter].
20. Lambe M., Wigertz A., Holmqvist M., Adolfsson J., Bardage G., Fornander T., et al. Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Res Treat 2009, Epub ahead of print. 10.1007/s10549-009-0615-7.
21. Katalinic A., Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008, 107:427-430.
22. Kumle M. Declining breast cancer incidence rates and decreased HRT use. Lancet 2008, 372:608-610.
23. Chlebowski R.T., Kuller L.H., Prentice R.L., Stefanick M.L., Manson J.E., Gass M., et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009, 360:573-587.
24. Chernichovsky D Not "Socialized Medicine" - an Israeli View of Health Care Reform. N Engl J Med 2009, 361((November 19) 21):e46. Epub 2009 Nov 4.
25. Bendelac J. Membership in sick funds 2009, National Insurance Institute, Research and Planning Administration, Jerusalem, June 2010 Hebrew.
26. Barchana M., Liphshitz I., Rozen P. Trends in colorectal cancer incidence and mortality in the Israeli Jewish ethnic population. Fam Cancer 2004, 3:207-214.
27. Cleveland W.S. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979, 74:829-836.
28. Chambers J.M., Cleveland W.S., Kleiner B., Tukey P.A. Graphical methods for data analysis 1983, Wadsworth, Belmont, CA.
29. Box G.E.P., Jenkins G.M. Time series analysis: forecasting and control 1976, Holden-Day, Oakland, CA.
30. Berry D.A., Ravdin P.M. Breast cancer trends: a marriage between clinical trial evidence and epidemiology. J Natl Cancer Inst 2007, 99:1139-1141.
31. Menes T.S., Kerlikowske K., Jaffer S., Seger D., Miglioretti D.L. Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment: findings from the Breast Cancer Surveillance Cosortium. Cancer Epidemiol Biomarkers Prev 2009, 18:2822-2828.
32. Wakefield J. Ecologic studies revisited. Annu Rev Public Health 2008, 29:75-90.